MoonLake Immunotherapeutics - Class A Ordinary Shares MLTX 深 滬
等待開盤 12-06 09:30:00 美东时间
14.90
-0.095
-0.63%
華盛通- 最 高15.3386
- 今 開15.08
- 成交量 125.56万股
- 最 低 14.84
- 昨 收 14.995
- 總市值 9.46亿
- 52周最高 62.75
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 5.95
- 委 比 -95.14%
- 總股本 6350.14万
- 歷史最高 64.98
- 量 比 0.61
- 振 幅 3.33%
- 歷史最低 4.25
- 每 手 1
- 風險率 15.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
11-24 11:23
HC Wainwright & Co. Maintains Buy on MoonLake, Lowers Price Target to $26
HC Wainwright & Co. analyst Raghuram Selvaraju maintains MoonLake (NASDAQ:MLTX) with a Buy and lowers the price target from $30 to $26.
11-21 19:23
MoonLake Reports Clinical Data From Sonelokimab Studies, Nanobody Drug Shows Results In Multiple Trials For Rare Skin Diseases, Eyes FDA Filing In 2026
MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results
11-05 20:21
MoonLake Q3 EPS $(1.10) Misses $(0.88) Estimate
MoonLake (NASDAQ:MLTX) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(0.88) by 25.14 percent. This is a 96.43 percent decrease over losses of $(0.56) per share from the
11-05 20:13
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
Citigroup Downgrades MoonLake to Sell, Maintains Price Target to $5
Citigroup analyst Samantha Semenkow downgrades MoonLake (NASDAQ:MLTX) from Neutral to Sell and maintains the price target from $5 to $5.
10-30 03:54
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MapLight Therapeutics completed its initial public offering, raising $296.3 million through the sale of 16.96 million shares at $17 each, including underwriters' option exercise. The shares, trading under "MPLT" on the Nasdaq, began on October 27. Morgan Stanley, Jefferies, Leerink Partners, and Stifel led the offering. MapLight focuses on treatments for CNS disorders like schizophrenia and Alzheimer's disease psychosis, with its lead candidate i...
10-29 13:06
Top 3 Health Care Stocks That Are Preparing To Pump In Q4
The most oversold stocks in the health care sector presents an opportunity to b...
10-06 18:23
HC Wainwright & Co. Downgrades MoonLake to Neutral
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades MoonLake (NASDAQ:MLTX) from Buy to Neutral.
10-02 18:43
